Back

In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Antithrombotic therapy in acute coronary syndromes and PCI Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Sem A O F Rikken

St Antonius Hospital, Nieuwegein (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
Doctor A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial
Professor R. Mehran (New York City, US)
Abstract Slides Video
Presentation thumbnail
Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
Doctor S. Godtfredsen (Aalborg, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy in acute coronary syndromes and PCI

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
thumbnail
Congress Presentation
Elderly patients are hyperresponsive to potent P2Y12 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources